Pricing Log in Create free account

Obsidian Therapeutics, Inc (OBX) vs Rigel Pharmaceuticals, Inc. (RIGL)

Obsidian Therapeutics, Inc and Rigel Pharmaceuticals, Inc. are both Biotechnology companies. Obsidian Therapeutics, Inc and Rigel Pharmaceuticals, Inc. are of similar size ($838.3M and $795.6M). Across the 5 metrics below, Rigel Pharmaceuticals, Inc. leads on 4 and Obsidian Therapeutics, Inc on 1.

Valuation

Metric OBX RIGL Biotechnology median
P/E — 2.64 11.58
P/S n/m 2.88 9.61
P/B n/m 1.87 2.26
Price to free cash flow n/m 42.58 26.41
EV/EBITDA n/m 9.44 0.72
EV/Sales n/m 2.59 9.43
Earnings yield — 37.87% (32.28%)
Free cash flow yield 0.00% 2.35% (22.27%)

Profitability

Metric OBX RIGL Biotechnology median
Gross margin — 89.64% 68.81%
Operating margin — 26.28% 0.00%
Net margin — 106.59% 0.00%
Free cash flow margin — 6.72% 0.00%
Return on equity — 109.18% (50.30%)
Return on assets — 80.16% (45.47%)
Return on invested capital 0.00% 13.69% 0.00%

Growth

Metric OBX RIGL Biotechnology median
Revenue growth (TTM) — 2.18% 6.78%
EPS growth (last fiscal year) (11.60%) 1,867.68% 29.88%
Revenue growth, 5-year CAGR — 22.06% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric OBX RIGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.21 2.39 4.74
Net debt to EBITDA 0.77 (1.05) 1.01

Dividend

Metric OBX RIGL Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric OBX RIGL Biotechnology median
Market cap 795.63m 838.31m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack